ANDREW LEBSON: Open Payments
NPI 1043755952 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$757 in 35 payments from 19 companies in 2025. Trend: 2023 $1,217 · 2024 $981 · 2025 $757
Food & beverage: $757
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $190 |
| Novo Nordisk Inc | 3 | $69 |
| Amgen Inc. | 3 | $58 |
| Radius Health, Inc. | 2 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Medtronic, Inc. | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $40 |
| BETA BIONICS, INC. | 1 | $35 |
| Insulet Corporation | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
Products named: MOUNJARO, JARDIANCE, Tymlos, UNITHROID, TEPEZZA, MINIMED 780G, CRENESSITY, iLet Bionic Pancreas.
Industry payments across MD — which companies pay providers there.
